|
WO2020113137A1
|
|
Methods and systems for wavelength mapping cardiac fibrillation and optimizing ablation lesion placement
|
|
US2020138319A1
|
|
Methods and systems for wavelength mapping cardiac fibrillation and optimizing ablation lesion placement
|
|
AU2017370535A1
|
|
Catheters, systems, and related methods for mapping, minimizing, and treating cardiac fibrillation
|
|
US2017079542A1
|
|
Catheters, systems, and related methods for mapping, minimizing, and treating cardiac fibrillation
|
|
US2015329635A1
|
|
Suppression of leptin action for treatment of pulmonary infections
|
|
WO2015073836A1
|
|
Compositions and methods for treating cryptosporidiosis
|
|
US2015050682A1
|
|
Direct assay of thioredoxin reductase activity
|
|
US2016058839A1
|
|
Leptin for treating systemic inflammatory response syndrome
|
|
WO2014169111A1
|
|
Decellularization and recellularization of whole organs
|
|
US2014275293A1
|
|
Measurement and analysis of molecular interactions
|
|
WO2014138682A1
|
|
Compositions and methods for cardiac tissue repair
|
|
WO2014137845A1
|
|
Systems and methods for random-access power management using packetization
|
|
US2016007882A1
|
|
Device and method for lung measurement
|
|
WO2014116883A1
|
|
Device for improved prevention of infectious contamination in intravenous ("iv") components
|
|
US2014127231A1
|
|
p38 MAPK Pathway Inhibitors as Female-Specific Therapeutics
|
|
WO2014018618A1
|
|
Methods and compounds for diagnosing threonyl-trna synthetase-associated diseases and conditions
|
|
WO2014018620A1
|
|
Methods and compounds for reducing threonyl-trna synthetase activity
|
|
WO2013192364A1
|
|
Treatments of oxidative stress conditions
|
|
EP2856172A1
|
|
Compositions and methods for assaying platelet reactivity and treatment selection
|
|
US2014200575A1
|
|
Methods and systems for optimizing lesion placement to minimize and treat cardiac fibrillation
|
